ArQule, Daiichi Sankyo discontinue lung cancer drug trial

ArQule, Daiichi Sankyo discontinue lung cancer drug trial
(Reuters) - Biotechnology company ArQule Inc and Japan's Daiichi Sankyo Co Ltd said they will discontinue a late-stage trial of their experimental lung cancer drug after an interim analysis showed it would not meet the main goal of improving overall survival. "This is their single-most important asset. The drug may be dead, which may leave the company trading down to cash," said Chad Messer, an analyst with Needham & Company. ArQule's shares were down 61 percent at $1.94 before the bell on Tuesday. They closed at $4.99 on Monday on the Nasdaq. ...
Source: news.yahoo.com

Cargill to build canola-crushing plant in Alberta

WINNIPEG, Manitoba (Reuters) - Cargill Ltd plans to build a canola-crushing plant near Camrose, Alberta, to take advantage of steadily growing Canadian plantings of the oilseed, the U.S. agribusiness giant said on Monday. Canada, the world's biggest producer and exporter of canola, which is crushed to produce vegetable oil and meal, has steadily increased its plantings to what some expect will amount to a record-large harvest this year. Canadian crushing capacity has also expanded in recent years as demand builds from overseas and the United States for the processed products. ... Click here to read the rest

How to Get Clear Skin Fast - Surefire Ways for Getting Soft and Younger Looking Skin ASAP

How to Get Clear Skin Fast - Surefire Ways for Getting Soft and Younger Looking Skin ASAP
The main purpose of writing this article is to help all those individuals who want to get rid of skin problems on permanent basis. I have shared easy and simple ways of getting fresh and younger looking skin in this article. The good thing is that these methods give results ASAP.
Source: EzineArticles.com

Overnight dementia care gives caregivers some rest

Overnight dementia care gives caregivers some rest
Just after 10 p.m., when most people their age are going to sleep, a group of elderly folks suffering from dementia are just getting started, dancing and shaking tambourines and maracas in a raucous version of "La Bamba."
Source: news.yahoo.com

Cancer trials show one year on Roche's Herceptin is best

Cancer trials show one year on Roche's Herceptin is best

LONDON (Reuters) - Extending treatment with Roche's breast cancer drug Herceptin to two years from the one year current standard is not worth while, trial data showed on Monday, but shortening treatment to six months also looks unlikely to benefit patients. The results of two keenly-watched studies on Herceptin, known generically as trastuzumab, banish a downside risk for Roche, but also limit its ability to squeeze more value out of the lucrative drug before it loses its patent from 2014. Analysts had said the Swiss firm, the world's biggest maker of cancer drugs, could lose up to $1. ...

Source: news.yahoo.com